Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

XTL Biopharmaceuticals Reports First Half 2018 Financial Results & Provides Update

XTL Biopharmaceuticals
Posted on: 25 Jul 18

RAMAT GAN, Israel, July 24, 2018 /PRNewswire/ -- XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) (TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing treatments for autoimmune diseases, today announced financial results for the quarter ended June 30, 2018 and provided an update on the development program for its lead drug candidate hCDR1.

The Company is expanding its IP portfolio surrounding hCDR1 and has decided to reduce its research and development expenditures in connection with execution of its clinical trials. In parallel, the Company searches to identify additional assets to add to XTL's portfolio.

Financial Overview

XTL reported approximately $1.1 million in cash and cash equivalents as of June 30, 2018 and approximately $5 million in Other Current Assets (mainly short term bank deposits). The decrease of $2.2 million since December 31, 2017, in cash and cash equivalents derives mainly from depositing additional $1.8 million to the short-term bank deposit.

Research and development expenses for the six months ended June 30, 2018 were $20 thousand compared to $38 thousand for the corresponding period in 2017. The decrease was due to management decision to reduce its research and development expenditures on its current drug.

General and administrative expenses for the six months ended June 30, 2018 were $362 thousand compared to $732 thousand for the corresponding period in 2017. The change resulted mainly from decreases in salaries and expenses relating to employees (including stock-based compensation expenses) and investor relations.

Finance income, net for the six months ended June 30, 2018 were $1,291 thousand compared to finance expenses, net amounted to $1,595 thousand for the corresponding period in 2017. The difference is driven primarily by revaluation of warrants. During the first quarter of 2018 the Company filed an F-1 amendment and registered its warrants. Subsequently, all warrants were classified to the capital and there will be no further future evaluations. Another reason for the difference is the revaluation of marketable securities (investment in stocks of InterCure Ltd.).

XTL reported an operating loss for the six months ended June 30, 2018 of $382 thousand compared to $770 thousand for the corresponding period in 2017 reflecting decreased spending on research and development and general and administrative expenses. The Company reported a total net income for the period ended June 30, 2018 of approximately $909 thousand or $0.002 per share, compared to a loss of  approximately $2,403 thousand or $0.006 per share in the corresponding period in 2017.  The change is driven primarily by the revaluation of warrants as described above.

For more information:
www.prnewswire.com/news-releases/xtl-biopharmaceuticals-reports-first-half-2018-financial-results--provides-update-300685556.html

Editor's Details

Mike Wood
PharmiWeb.com
www.pharmiweb.com
editor@pharmiweb.com

Last updated on: 25/07/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.